Knee osteoarthritis (OA) is conceptualized primarily as a cartilage disease. Growing scientific evidence tells a more complicated story one of synovial irritation, subchondral bone remodelling and progressive joint damage that cannot be solved through cartilage repair alone. “Why Thailand has transformed into an MSC knee destination, what the treatments actually treat and whe benefits patients need to learn before making a trip abroad.
Traveling to another country for a medical procedure is not something that anyone does lightly. It requires research, expense, logistics and an amount of trust not typically granted by patients without good cause. Thailand has increasingly moved onto the radar of a growing number people with moderate-to-severe knee osteoarthritis — those who have exhausted physiotherapy, gone through corticosteroid injections on numerous occasions and been told that joint replacement is really their only realistic option. Not due to botanical balms or FDA loopholes, but because a few well-prepared Thai centers are offering something nearly no Western orthopaedic systems have yet routinely been able to: stem cell therapy for knee joints in clinically-sound, properly monitored conditions.
To appreciate why this is important, it helps to remember what knee OA really is — andwhy the cartilage-repair framing that dominates the discussion misses much of a more complete picture.
Osteoarthritis Is an Entropic Joint Disease, Not Just a Cartilage Issue
The most apparent and often discussed feature of knee osteoarthritis is cartilage degradation. However, osteoarthritis exists as a disease of the entire joint. The synovial membrane — that layer of tissue lining the joint capsule, and which produces a highly lubricating fluid to ease movement in joints — is chronically inflamed; it secretes proinflammatory cytokines (including IL-1β [interleukin 1 beta], TNFα and IL-6) that actively drive cartilage destruction. The subchondral bone, the dense layer of tissue beneath cartilage at a joint surface, subsequently remodels its structure in response to changes or alterations in load across the joint. Periarticular muscles weaken. Proprioception deteriorates. When defined as a biological system, the joint degenerates reproducibly across all tissues over time.
Hence, the reason why cartilage-focused interventions — from microfracture surgery to autologous chondrocyte implantation (ACI) and even simple viscosupplementation — yield partial, temporary outcomes. They are targeting only one aspect of a multi-tissue process. MSC therapy on the other hand is engineered to target this joint environment — that inflammatory and degenerative milieu in which all of those tissues are failing.
Figure 1. Stem Cell Therapy for Knee Osteoarthritis in Thailand: Beyond Cartilage Repair
What MSC Therapy Is Actually Doing in a Knee Joint
MSCs do not become new cartilage cells when delivered into a knee joint (usually intra-articularly [IA] yes some are IV) The most important mechanism of action for these secretome type treatments is paracrine: they release a cocktail of bioactive molecules that alter the joint environment away from one conducive to degeneration and towards tissue protective mechanisms as well as dampening inflammatory drivers.
Clinical evidence for the use of MSC therapy in knee osteoarthritis is more advanced than that found across many other regenerative medicine indications. In a systematic review from the journal Stem Cells Translational Medicine in 2021, assessing data of seventeen randomised and controlled studies showed significant improvements by decreasing pain scores accompanied with functional outcome parameters and quality of life measures after receiving MSC-based intra-articular therapy compared to respective controls. In several MRI-monitored cohorts, improved cartilage quality was also reported with variable magnitude and durability.
Why Knee Treatment in Thailand
Orthopaedics and sports medicine in Thailand represents one of the most advanced areas within Southeast Asia. Many Bangkok hospitals are JCI-accredited and handle large volumes of complicated knee cases — even the occasional professional athlete from across the region, giving its surgical and regenerative medicine teams extensive clinical experience in what is often a unique setting for lower volume centres.
In Thailand, regenerative programmes for knee osteoarthritis usually consist of intra-articular MSC injection together with structured physiotherapy rehabilitation programme combined with nutritional support to enhance joint health and follow-up imaging at regular intervals.
Patients who are the best candidates for meaningful outcomes are those classified in Kellgren-Lawrence grade II to III of moderate osteoarthritis with preserving joint space but implement dedicating function rehabilitation such as gym workouts very seriously along with performing the cell therapy itself. MSCs normalize the biological environment. That is what rehabilitation trains the joint to do inside it.
Approaching This Decision Well
Knee replacement surgery is not a failure. It is still the most consistently successful treatment option available for advanced osteoarthritis used when there’s bone-on-bone contact with extreme limitation of function (grade IV). MSC therapy is a treatment for patients who need help but do not warrant surgery.
For those yet to reach this stage, what may it provide — a substantial delay in progression, reduced daily pain and anti-inflammatory medication burden and improved functional capacity rendering the coming decades looking much different? That is not a small thing. If, as a patient has been advised to wait until joints become so problematic for replacement surgery — this may be the single most clinically appropriate option available at present — and Thailand, when practised at its best there are some of the most experienced teams in world.
References
Ayala-Cuellar, M., Kang, J.H., Jeung, E.B., & Choi, K.C. (2019). Roles of mesenchymal stem cells in tissue engineering and regenerative medicine. International Journal of Molecular Sciences, 20(5), 1–17.
Filardo, G., Perdisa, F., Roffi, A., Marcacci, M., & Kon, E. (2016). Stem cells in articular cartilage regeneration. Journal of Orthopaedic Surgery and Research, 11(1), 42.
Hunter, D.J., & Bierma-Zeinstra, S. (2019). Osteoarthritis. The Lancet, 393(10182), 1745–1759.
Matas, J., Orrego, M., Amenabar, D., et al. (2019). Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: Repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomised phase I/II trial. Stem Cells Translational Medicine, 8(3), 215–224.
Pers, Y.M., Rackwitz, L., Ferreira, R., et al. (2016). Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial. Stem Cells Translational Medicine, 5(7), 847–856.